Study Title
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Protocol ID
AAML1531
Condition/s
Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm
Diagnosis Stage
New diagnosis
Location
NSW, VIC, WA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Perth Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
90 days to 4 years
International registry ID's
NCT02521493
| Study Title | AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome |
|---|---|
| Protocol ID | AAML1531 |
| Disease (Sub Disease) | Acute Myeloid Leukemia Down Syndrome Myelodysplastic Syndrome Myeloid Leukemia Associated With Down Syndrome Myeloproliferative Neoplasm |
| Diagnosis Stage | New diagnosis |
| Location | NSW / VIC / WA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02521493 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 03/11/2015 |
| Sites | The Children's Hospital at Westmead / John Hunter Children's Hospital / Perth Children's Hospital / Sydney Children's Hospital / Royal Children's Hospital / Christchurch Hospital / Starship Hospital/ |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 90 days to 4 years |
| International registry ID's | NCT02521493 |